Expenditures have increased and not the number of new medicines resulting from human-genome sequencing, says the author.


David C. Swinney is Principal at the Institute for Rare and Neglected Diseases Drug Discovery.
Expenditures have increased and not the number of new medicines resulting from human-genome sequencing, says the author.
